From Precision Drug Selection to Precision Drug Creation: Why Personalized mRNA Cancer Vaccines May Change the Pharmaceutical Model

For most of modern pharmaceutical history, therapeutic innovation has followed a stable sequence: discover or engineer a medicinal product, demonstrate its quality, safety and efficacy, manufacture essentially identical units at scale, and then identify the patients most likely to benefit. Precision medicine improved this model chiefly by improving drug selection. Genomic profiling and companion diagnostics allowed clinicians to match a pre-existing medicine to a molecularly defined patient subgroup. Personalized mRNA cancer vaccines introduce a more consequential possibility. Patient-specific tumour information can become an input into the design and manufacture of the medicinal product itself. Tumour sequencing, HLA biology, computational neoantigen prediction, algorithmic prioritization, mRNA engineering, GMP manufacturing and clinical delivery form a continuous production system in which biological data are converted into a patient-specific therapeutic specification. The August 2026 positive Phase III announcement for intismeran autogene plus pembrolizumab in resected melanoma gives this transition new industrial credibility. Its significance extends beyond melanoma and even beyond mRNA: it suggests that a therapeutic platform can generate molecularly different products for different patients while remaining sufficiently standardized to support global, randomized, late-stage pharmaceutical development. This perspective examines the implications for artificial intelligence, manufacturing, quality assurance, regulation, intellectual property, health economics and corporate strategy. The central argument is that individualized medicines may shift the scalable pharmaceutical asset from an invariant molecule toward a validated system capable of generating different medicines reproducibly.